Alexion to Acquire Synageva for US$8.4 B to Diversify its Rare Disease Portfolio
By Heather Cartwright & Tridisha Goswami
Pharma Deals Review: Vol 2015 Issue 5 (Table of Contents)
Published: 29 May-2015
DOI: 10.3833/pdr.v2015.i5.2104 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Indicative of strong M&A appetite for orphan drug companies, Alexion Pharmaceuticals has agreed to acquire Synageva BioPharma in an US$8...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS